situation of patients with Alzheimer's disease. The results of the
analysis are presented in Berlin today. "With this retrospective data
analysis for the first time the drug supply situation of our
policyholders with Alzheimer's disease has shown. Our goal is to build
optimized in expert discussions of living and quality of care our
insured continuously," said the deputy chairman of Barmer, Birgit
Fischer, in berlin. After all, a result which is from the Institute of
Empirical Health Economics (IFEG) conducted cost analysis that about
one third of patients diagnosed with Alzheimer's dementia or
dementia-focused therapy or psychotropic drugs were given.
Approximately half of the patients received no specific anti-dementia
drugs, but were only with psychotropic drugs, hypnotics / sedatives or
treated.
To improve the quality of care of people with dementia continue to
Barmer health services research, this study of patients with
Alzheimer's disease has already started 2005 with Merz and the
Institute of Empirical Health Economics (IFEG). For the first time in
Germany were collected using anonymous payroll data from 2005, the
total cost and the cost structure of Barmer insured with Alzheimer's
disease. "For us as a pharmaceutical company with its own research, it
is necessary to perform high-quality care studies, in order not to do
research on the needs of over," said Dr. Eugene Wilbert, Director of
Marketing & Sales Merz Pharmaceuticals GmbH, Frankfurt.
Today's health care research takes the care of patients under everyday
conditions under the magnifying glass: It is a multidisciplinary,
problem-oriented research field that examines how financing systems,
organizational structures and processes, and health-related
technologies and other issues, the access to health care, the quality
and cost health care and health and well being of patients influence.
The study included a cost comparison of IFEG supply of three groups:
patients treated with memantine therapy, patients treated with
psychotropic drugs / hypnotics / sedatives and patients without a
dementia-focused therapy. A non-antidementive pharmacotherapy of
Alzheimer's dementia causes, especially in the higher maintenance
costs, the results of Prof. Dr. Reinhard Rychlik Institute of
Empirical Health Economics, University of Bochum. According to the
results, occurred in the total costs, despite higher drug costs
specific results in the best of memantine group.
"The Barmer is committed to an interdisciplinary collaboration of all
stakeholders in healthcare," said Fischer. "We are committed to our
ability to gain knowledge from data, to work for our affected
policyholders with a multiprofessional team on improvements to address
the particular disease."
No comments:
Post a Comment